Oppenheimer & Co. Inc. trimmed its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,974 shares of the conglomerate's stock after selling 2,146 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Danaher were worth $5,274,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its position in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the period. Bank of New York Mellon Corp lifted its stake in Danaher by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock worth $1,971,609,000 after purchasing an additional 441,012 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock valued at $1,417,342,000 after acquiring an additional 148,251 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate's stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Finally, Flossbach Von Storch SE lifted its holdings in Danaher by 1.2% during the 4th quarter. Flossbach Von Storch SE now owns 3,710,738 shares of the conglomerate's stock worth $851,800,000 after buying an additional 44,490 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on DHR shares. Robert W. Baird reduced their price objective on Danaher from $277.00 to $268.00 and set an "overweight" rating for the company in a research note on Tuesday, January 28th. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. Barclays reduced their target price on Danaher from $275.00 to $240.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Wells Fargo & Company lowered their price target on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Finally, Scotiabank began coverage on Danaher in a research report on Monday, December 23rd. They set a "sector perform" rating and a $265.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $278.00.
Read Our Latest Stock Analysis on Danaher
Insiders Place Their Bets
In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.10% of the company's stock.
Danaher Trading Up 1.0 %
DHR stock traded up $2.14 during mid-day trading on Tuesday, reaching $207.83. 3,862,462 shares of the stock traded hands, compared to its average volume of 4,529,283. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market cap of $148.54 billion, a P/E ratio of 39.32, a P/E/G ratio of 2.66 and a beta of 0.82. The stock's fifty day moving average is $224.11 and its 200-day moving average is $244.31.
Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the company posted $2.09 EPS. As a group, sell-side analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. This is a boost from Danaher's previous quarterly dividend of $0.27. Danaher's payout ratio is currently 24.24%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
